US cancer focused pharma Karyopharm Therapeutics saw its shares slide 12.4% to $5.06 by late morning, after it disclosed a ...
US immunology focused biotech Zenas BioPharma has entered into a license agreement with China’s InnoCare Pharma granting ...
Privately-held US biopharma Accent Therapeutics has announced an asset purchase agreement with Germany’s Boehringer Ingelheim ...
Portuguese antibody discovery specialist FairJourney Biologics has named Werner Lanthaler as chief executive, replacing ...
Swiss biotech Relief Therapeutics (SIX: RLF) has agreed to merge with privately held NeuroX Group in a transaction valuing ...
The US Food and Drug Administration (FDA) has approved Boehringer Ingelheim Jascayd (nerandomilast) tablets to treat ...
UK pharma major GSK’s clinical data for depemokimab positions the asset for potential Food and Drug Administration (FDA) ...
Venture financing for mRNA-based innovator vaccines saw an 82% decline from $510 million in 2023 to $90 million in 2025 ...
US biotech TORL BioTherapeutics has raised $96 million in a series C round to push its lead antibody-drug conjugate, ...
India’s micro, small and medium-sized drugmakers are pushing back against tougher manufacturing rules, warning they could ...
Takeda (TYO: 4502) sits in a peculiar place in global pharma. As Japan’s largest drugmaker, it retains a national heritage ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback